SUZHOU – November 03, 2026 -- CStone Pharmaceuticals (HKEX: 2616) will lead Phase I development of Kimia Therapeutics' potential first-in-class DNA damage response (DDR) cancer drug in mainland China and Australia, while Kimia reimburses the applicable clinical development costs.